Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents

Novavax Inc's NVAX Nuvaxovid (NVX-CoV2373) COVID-19 vaccine received expanded manufacturing and marketing approval in Japan for adolescents aged 12 through 17.
Novavax has partnered with Takeda Pharmaceutical Co Ltd TAK to develop, manufacture, and distribute Nuvaxovid in Japan.
The Australian Therapeutic Goods Agency has granted expanded approval for provisional registration of Nuvaxovid for adolescents aged 12 through 17.
Also Read: Novavax's COVID-19 Vaccine For Adults Gets CDC Advisory Committee Recommendation.
The expanded approval was based on data from the ongoing pediatric expansion of PREVENT-19 Phase 3 trial.
In the trial, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% overall clinical efficacy when the delta variant was the predominant circulating SARS-CoV-2 strain in the U.S.
Price Action: NVAX shares are down 0.58% at $55.19 during the market session on the last check Tuesday.
Photo by hakan german from Pixabay